KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) EBT Margin (2016 - 2025)

Novavax has reported EBT Margin over the past 16 years, most recently at 12.17% for Q4 2025.

  • Quarterly results put EBT Margin at 12.17% for Q4 2025, up 9549.0% from a year ago — trailing twelve months through Dec 2025 was 41.74% (up 6763.0% YoY), and the annual figure for FY2025 was 39.36%, up 6525.0%.
  • EBT Margin for Q4 2025 was 12.17% at Novavax, up from 288.22% in the prior quarter.
  • Over the last five years, EBT Margin for NVAX hit a ceiling of 77.98% in Q1 2025 and a floor of 373.39% in Q4 2021.
  • Median EBT Margin over the past 5 years was 65.48% (2023), compared with a mean of 99.7%.
  • Peak annual rise in EBT Margin hit 71676bps in 2021, while the deepest fall reached -495096bps in 2021.
  • Novavax's EBT Margin stood at 373.39% in 2021, then soared by 86bps to 51.63% in 2022, then fell by -17bps to 60.65% in 2023, then plummeted by -37bps to 83.32% in 2024, then soared by 115bps to 12.17% in 2025.
  • The last three reported values for EBT Margin were 12.17% (Q4 2025), 288.22% (Q3 2025), and 61.4% (Q2 2025) per Business Quant data.